Pandion Obtains $58 Million to Keep Developing Autoimmune and Bowel Disease Therapies

Pandion Obtains $58 Million to Keep Developing Autoimmune and Bowel Disease Therapies
Pandion Therapeutics has obtained $58 million in financing to continue developing treatments for autoimmune and inflammatory diseases, including bowel disorders. Polaris Partners, Versant Ventures and Roche Venture Fund led the financing round. SR One and BioInnovation Capital also participated. Pandion uses its proprietary technology platform to create bispecific antibodies. It engineers the artificial proteins to bind to two proteins

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Diane Jo Docks says:

    Interesting article. The goal of more targeted and effective therapy is what people with IBD need. None of the biologics I have taken have helped me. I recently started the latest Crohn’s craze (starts with an S), which was originally approved for a particular type of psoriasis. I swear it is making me worse. However, the BIG HOLE in the article is SIDE EFFECTS. There is no mention of making a SAFE medication. We don’t want medications that cause intractable headaches, cancer, inability to breath, horrific joint pain (the list goes on) and death.

Leave a Comment

Your email address will not be published. Required fields are marked *